Becton Dickinson & Co Stock Price, News & Analysis

BD (Becton, Dickinson and Company) announced early results for Morgan Stanley's cash tender offers for specific notes, with a maximum purchase price of $200 million. As of March 29, 2022, holders had validly tendered approximately $1.6 billion in notes, exceeding the maximum limit, which led to a pro-rata acceptance of Floating Rate Notes due June 2022, totaling $199 million. Other notes tendered will not be accepted. The Offers are subject to specific conditions as detailed in the Offer to Purchase.

BD (Becton, Dickinson and Company) has announced key details regarding the spin-off of its diabetes care business, Embecta Corp.. Shareholders of BD as of March 22, 2022 will receive one share of Embecta for every five shares of BD held. 'When issued' trading of Embecta is set to commence on March 21, 2022, under ticker EMBCV, with 'regular way' trading starting on April 1, 2022 under EMBC. The transaction is expected to be tax-free. BD shareholders should consult tax advisers for implications of this spin-off.

BD (Becton, Dickinson and Company) announced that Morgan Stanley has initiated cash tender offers for various notes, totaling a maximum combined purchase price of $200,000,000. The offers include multiple series of notes with varying acceptance priority levels and offer details, including early tender premiums. The offers are scheduled to expire on April 12, 2022, with an early tender date of March 29, 2022. Holders of the notes must tender by these deadlines to receive maximum consideration. The company emphasizes the offers' conditions based on the successful completion of a financing transaction.

BD (Becton, Dickinson and Company) has appointed William "Bill" Brown to its board of directors effective February 28, 2022. Brown, an experienced executive, is currently the executive chair of L3Harris Technologies with $18 billion in annual revenue. He previously served as chair and CEO of L3Harris from July 2019 to June 2021. BD's chairman, Tom Polen, expressed confidence in Brown's leadership skills to support the company's BD2025 strategy aimed at long-term stakeholder value. Having degrees in engineering and an MBA, Brown also holds several board positions.

BD (Becton, Dickinson and Company) will present virtually at the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 9:50 a.m. ET. The event is accessible via a live webcast on the BD investor relations website, and a replay will be available afterward. BD, a leading global medical technology company, focuses on enhancing health care through innovative solutions. With a workforce of approximately 75,000, the company supports health care providers in improving safety and efficiency in patient care.

BD (Becton, Dickinson and Company) has appointed Shana Neal as the new chief people officer, effective April 4, 2022. Neal, who previously held various HR positions at BD from 2005 to 2018, will oversee global HR functions, including Talent Acquisition, Total Rewards, and Diversity initiatives. She replaces Betty Larson, who is transitioning to a new role in the healthcare sector. BD's CEO Tom Polen expressed confidence in Neal's leadership skills and industry knowledge as essential for advancing BD's 2025 strategy and enhancing stakeholder value.

BD (Becton, Dickinson and Company) announced that its diabetes care business, embecta, will spin off on April 1, 2022. To prepare investors, embecta will host a virtual Investor Event on March 7, 2022, starting at 8 a.m. Eastern Time. Presenters include CEO Dev Kurdikar and CFO Jake Elguicze, discussing the company's products, market opportunities, and financial strategies. A Q&A session will follow. More details and a link to the event are available on BD's investor webpage, with a replay accessible post-event.